Abstract:Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which minimally requires two other subunits, EED and SUZ12, for enzymatic activity. EZH2 has been traditionally known to mediate histone H3K27 trimethy-lation, a hallmark of silent chromatin. Emerging evidence indicates that EZH2 also activates gene expression in cancer cells in a context distinct from canonical PRC2. The molecular mechanism underlying the functional conversion of EZH2 from a gene re-pressor to an activator is unclear. Here, we show that EZH2 harbors a hidden, partially disordered transactivation domain (TAD) capable of interacting with components of active transcrip-tion machinery, mimicking archetypal acidic activators. The EZH2 TAD comprises the SRM (Stimulation-Responsive Motif) and SANT1 (SWI3, ADA2, N-CoR, and TFIIIB 1) regions that are normally involved in H3K27 methylation. The crystal structure of an EZH2-EED binary complex indicates that the EZH2 TAD mediates protein oligomerization in a noncanonical PRC2 context and is en-tirely sequestered. The EZH2 TAD can be unlocked by cancer -specific EZH2 phosphorylation events to undergo structural tran-sitions that may enable subsequent transcriptional coactivator binding. The EZH2 TAD directly interacts with the transcriptional coactivator and histone acetyltransferase p300 and activates gene expression in a p300-dependent manner in cells. The correspond-ing TAD may also account for the gene activation function of EZH1, the paralog of EZH2. Distinct kinase signaling pathways that are known to abnormally convert EZH2 into a gene activator in cancer cells can now be understood in a common structural con-text of the EZH2 TAD.

Focus on the classical and non-classical functions of EZH2: Guide the development of inhibitors and degraders

Global Characterization of Proteome and Lysine Methylome Features in EZH2 Wild-Type and Mutant Lymphoma Cell Lines.

The roles of EZH2 in cancer and its inhibitors

No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function

EZH2: a novel target for cancer treatment

EZH2 can be used as a therapeutic agent for inhibiting endothelial dysfunction

Targeting EZH2 for cancer therapy: From current progress to novel strategies

Easy or Not—The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity

The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy

Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader

The Noncanonical Role of EZH2 in Cancer.

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

EZH1/2 as targets for cancer therapy

Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic

Regulation of Chromosome Regulator EZH2 in Cancer Epigenetics and EZH2 Targeted Drugs in Cancer Therapy

Treating human cancer by targeting EZH2

Dual-target EZH2 inhibitor: latest advances in medicinal chemistry

A Partially Disordered Region Connects Gene Repression and Activation Functions of EZH2

The functions of EZH2 in immune cells: Principles for novel immunotherapies

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas